Clinical Trials
5 trialsNCT05119855 2026-02-05
Safety and Immunogenicity of 9-valent Human Papillomavirus (9vHPV) Vaccine Coadministered With Messenger Ribonucleic Acid (mRNA)-1273 Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) (COVID-19) Vaccine (V503-076)
Merck Sharp & Dohme LLC
Phase 3 Completed
NCT04761822 2025-08-12
SARS
National Institute of Allergy and Infectious Diseases (NIAID)
Phase 2 Completed
NCT04847050 2024-08-27
A Trial of the Safety and Immunogenicity of the COVID-19 Vaccine (mRNA-1273) in Participants With Hematologic Malignancies and Various Regimens of Immunosuppression, and in Participants With Solid Tumors on PD1/PDL1 Inhibitor Therapy
National Institutes of Health Clinical Center (CC)
Phase 2 Completed
NCT05007860 2023-07-07
Vaccine Responsiveness in Patients With Chronic Lymphocytic Leukemia
Massachusetts General Hospital
Completed
NCT05054218 2023-04-14
COVID-19 Immunogenicity of a Third Dose of mRNA-1273 Vaccine Among Cancer Patients
H. Lee Moffitt Cancer Center and Research Institute
Completed